Dr Yang on the Activity of Cadonilimab/Chemo in Recurrent/Advanced Endometrial Carcinoma

“Overall, the AEs are manageable––17.8% [of] patients experienced grade 3 [or] 4 [events], so all these outcomes are promising.”

Sun Yang, MD, vice president of Fujian Cancer Hospital, chief physician and doctoral supervisor of Fujian Medical University, discussed the efficacy and safety of cadonilimab plus chemotherapy as first-line treatment for patients with recurrent/advanced endometrial carcinoma.

Cadonilimab, a bispecific immunotherapy targeting PD-1 and CTLA-4 pathways, is designed to enhance antitumor immune responses while potentially maintaining a manageable safety profile. When combined with standard chemotherapy, the regimen demonstrated notable clinical activity in this difficult-to-treat population, Yang illustrated.

The median progression-free survival (PFS) in the multi-center, single-arm phase 2 CARE trial (NCT06066216) was 17.77 months, underscoring a meaningful delay in disease progression compared with historical expectations in this setting. At the time of analysis, median overall survival (OS) had not been reached, suggesting the potential for durable benefit, although longer follow-up will be necessary to confirm these outcomes, according to Yang.

From a safety standpoint, the combination regimen appeared tolerable overall. Grade 3 or 4 treatment-related adverse effects were observed in 17.8% of patients, indicating that although higher-grade toxicities were present, they occurred in a relatively limited proportion of the study population, Yang noted. These findings suggest that the addition of cadonilimab does not substantially compromise the tolerability profile typically associated with chemotherapy.

Taken together, the efficacy and safety data from this study support further investigation of cadonilimab in combination strategies for endometrial cancer. The promising PFS signal, coupled with an unreached OS and manageable toxicity profile, positions this regimen as a potentially impactful option in the frontline setting for patients with recurrent or advanced disease.

Ongoing and future randomized trials will be critical to validate these findings and determine how this approach may be integrated into evolving treatment paradigms.